SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH

Key Points

• SG Americas Securities LLC bought a new stake of 18,565 shares (~$765,000) in Dianthus in Q4, and institutional investors now own about 47.53% of the company with several firms recently adding or increasing positions.
• Dianthus reported quarterly EPS of ($1.43), missing estimates of ($0.97) despite $0.57M in revenue, and shows extremely negative net margins and ROE while analysts project roughly -2.61 EPS for the year.
• Insiders have sold a total of 323,021 shares (~$26.56M) in the past three months (insiders own 8.15%), even as analysts on average rate the stock a Buy with an average price target of $115.55 (some targets up to $132).

SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 18,565 shares of the company's stock, valued at approximately $765,000.

Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust raised its holdings in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company's stock worth $37,000 after buying an additional 540 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $64,000. Tower Research Capital LLC TRC lifted its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Finally, Glenmede Investment Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at approximately $213,000. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Trading Down 2.1%

Shares of DNTH stock opened at $89.77 on Friday. Dianthus Therapeutics, Inc. has a 12-month low of $15.25 and a 12-month high of $92.27. The stock has a market capitalization of $3.99 billion, a P/E ratio of -21.90 and a beta of 1.22. The firm's 50 day moving average is $67.46 and its 200 day moving average is $49.70.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

DNTH has been the subject of a number of recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group set a $98.00 target price on Dianthus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 9th. Wolfe Research initiated coverage on Dianthus Therapeutics in a research note on Thursday. They issued an "outperform" rating and a $98.00 price target for the company. Robert W. Baird increased their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an "outperform" rating in a research report on Tuesday, March 10th. Finally, William Blair reiterated an "outperform" rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $115.55.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CEO Marino Garcia sold 122,918 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $10,016,587.82. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 323,021 shares of company stock worth $26,564,008 in the last three months. 8.15% of the stock is owned by insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.